GlassScriptPhysician profile
Iqbal Khan
NPI 1003967977
$1,720.37
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.44 · 2020: $17.44 · 2021: $67.19 · 2022: $499 · 2023: $839 · 2024: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.53 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $249.98 | 2023 | Wakix |
| Abbvie INC. | $216.69 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $159.17 | 2023 | Aptiom |
| Lilly USA, LLC | $141.43 | 2022-2023 | Emgality, Reyvow |
| Sunovion Pharmaceuticals INC. | $120.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $106.38 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $84.50 | 2023-2024 | Austedo Xr |
| Sk Life Science, INC. | $83.61 | 2023-2024 | |
| Biogen, INC. | $76.84 | 2021-2024 | Vumerity |
| Catalyst Pharmaceuticals, INC. | $65.42 | 2024 | |
| Ge Healthcare | $44.14 | 2022 | |
| Abbott Laboratories | $40.60 | 2022-2024 | Jot Dx |
| Nevro Corp. | $39.56 | 2022-2023 | Senza |
| Celgene Corporation | $39.05 | 2022-2023 | Zeposia |
| Lundbeck LLC | $35.41 | 2023 | Vyepti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.23 | 2023 | Ocrevus, Enspryng |
| Inspire Medical Systems, INC. | $33.99 | 2023 | Inspire |
| Amgen INC. | $32.99 | 2022 | |
| Penumbra, INC. | $32.44 | 2019 | |
| Neurocrine Biosciences, INC. | $18.15 | 2023 | Ongentys, Ingrezza |
| Ucb, INC. | $17.44 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.41 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.63 | 2023 | |
| Acadia Pharmaceuticals INC | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqbal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.